Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Aravive, Inc. ARAV
$1.65
-$0.07 (-4.07%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
101736160.00000000
-
week52high
2.46
-
week52low
0.58
-
Revenue
9137000
-
P/E TTM
-1
-
Beta
2.35986100
-
EPS
-2.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 03 июн 2022 г. | |
| BTIG | Buy | 08 мар 2021 г. | |
| William Blair | Outperform | 18 сент 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 23 июл 2020 г. |
| H.C. Wainwright | Buy | Buy | 27 мар 2020 г. |
| HC Wainwright & Co. | Buy | Buy | 25 окт 2022 г. |
| Piper Sandler | Overweight | Overweight | 14 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dove Leonard Scott | A | 400000 | 400000 | 01 февр 2023 г. |
| HOWARD RUDY | A | 400000 | 400000 | 01 февр 2023 г. |
| Geller Robert B. | A | 400000 | 400000 | 01 февр 2023 г. |
| McIntyre Gail Frances | A | 700000 | 700000 | 01 февр 2023 г. |
| Ho Peter Tai-Ching | A | 27176 | 27176 | 24 окт 2022 г. |
| Ho Peter Tai-Ching | A | 27177 | 27177 | 24 окт 2022 г. |
| Ho Peter Tai-Ching | A | 55353 | 54353 | 24 окт 2022 г. |
| Zhang Eric | A | 271768 | 271768 | 24 окт 2022 г. |
| Zhang Eric | A | 271769 | 271769 | 24 окт 2022 г. |
| Zhang Eric | A | 1403303 | 543537 | 24 окт 2022 г. |
Новостная лента
What Makes Aravive (ARAV) a New Buy Stock
Zacks Investment Research
17 апр 2023 г. в 13:43
Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
7 Short-Squeeze Stocks That Are Driving Hedge Funds Crazy
InvestorPlace
16 апр 2023 г. в 14:14
Although the concept of gambling on short-squeeze stocks present risks, certain market ideas drive hedge funds crazy. By this statement, I'm referring to companies that speculators believe in their hearts should tumble for various reasons.
7 Short-Squeeze Stocks That Could Explode in April
InvestorPlace
30 мар 2023 г. в 14:07
While an extremely risky proposition, short-squeeze stocks – as meme traders demonstrated – can occasionally yield radical profitability. However, you don't want to just pick any beaten-down security as a possible comeback candidate.
Aravive (ARAV) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
15 мар 2023 г. в 09:56
Aravive (ARAV) delivered earnings and revenue surprises of -39.39% and 298.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MDA Breakout Stocks Week 9 - March 2023: High-Frequency Gainers To Give You An Edge
Seeking Alpha
26 февр 2023 г. в 09:37
Two new Breakout Stocks for Week 9 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +35.8% YTD. This week, the Momentum Gauges® turned negative for the first time in 2023 with an early negative test signal Feb. 3rd warning of deteriorating market conditions.